The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trialMichael E. Nassif, Mikhail Kosiborod, Robert Gordon et al.|Nature Medicine|2021Cited by 599
In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection FractionVishal N. Rao, Stephen J. Greene, Evan Murray et al.|Journal of the American College of Cardiology|2021Cited by 93
Baseline Characteristics of Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF TrialScott D. Solomon, Dirk von Lewinski, John W. Ostrominski et al.|European Journal of Heart Failure|2024Cited by 62
Insulin resistance is associated with subclinical myocardial dysfunction and reduced functional capacity in heart failure with preserved ejection fractionBrent Gudenkauf, Allison G. Hays, Gabriel E. Shaya et al.|Journal of Cardiology|2023Cited by 22
Coronary Artery Calcium for Risk Stratification of Heart Failure Mortality: The Coronary Artery Calcium ConsortiumOmar Mhaimeed, Michael J. Blaha, Zeina Dardari et al.|Journal of Cardiac Failure|2024Cited by 3